Search company, investor...

Solace Pharmaceuticals

solacepharma.com

Founded Year

2006

Stage

Unattributed VC | Alive

Total Raised

$21.75M

Last Raised

$6.75M | 15 yrs ago

About Solace Pharmaceuticals

Solace Pharmaceuticals research and development programs are focused on exploiting biological understanding of disease targets that play a role in the pathogenesis of pain and that have disease-modifying potential in two key areas: modulating the activity of glial cells and intervening in the tetrohydrobiopterin (BH4) pathway. SLC022, the company's lead drug candidate, is in phase II clinical development in patients with post-herpetic neuralgia (PHN).

Headquarters Location

222 Berkeley Street Suite 1040

Boston, Massachusetts, 02116,

United States

Missing: Solace Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Solace Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Solace Pharmaceuticals Patents

Solace Pharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/14/2013

9/20/2016

Environmental engineering, Sewerage, Water treatment, Waste treatment technology, Sanitation

Grant

Application Date

5/14/2013

Grant Date

9/20/2016

Title

Related Topics

Environmental engineering, Sewerage, Water treatment, Waste treatment technology, Sanitation

Status

Grant

Solace Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Solace Pharmaceuticals founded?

    Solace Pharmaceuticals was founded in 2006.

  • Where is Solace Pharmaceuticals's headquarters?

    Solace Pharmaceuticals's headquarters is located at 222 Berkeley Street, Boston.

  • What is Solace Pharmaceuticals's latest funding round?

    Solace Pharmaceuticals's latest funding round is Unattributed VC.

  • How much did Solace Pharmaceuticals raise?

    Solace Pharmaceuticals raised a total of $21.75M.

  • Who are the investors of Solace Pharmaceuticals?

    Investors of Solace Pharmaceuticals include Polaris Partners, InterWest Partners and Hercules Capital.

  • Who are Solace Pharmaceuticals's competitors?

    Competitors of Solace Pharmaceuticals include Asuragen, Esperance Pharmaceuticals, Aegerion Pharmaceuticals, Selexys Pharmaceuticals, Phrixus Pharmaceuticals, Neurogesx, Elevation Pharmaceuticals, Protez Pharmaceuticals, Ren Pharmaceuticals, Renovis and 12 more.

Compare Solace Pharmaceuticals to Competitors

C
Cervelo Pharmaceuticals

Cervelo Pharmaceuticals is a semi-virtual clinical development company founded in 2006. The Company is focused on the in-licensing and development of mid stage neurology small molecule drug candidates. It currently has exclusive worldwide rights for all indications to a small molecule, first in class, drug candidate, which has demonstrated a safe and potentially effective capability against neuropathic and inflammatory pain, as well as inflammation.

E
Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

I
INDENA SPA

Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

S
St Charles Pharmaceuticals

St Charles Pharmaceuticals, Inc. is a CNS drug development company exploiting approaches to therapeutic intervention by targeting the crossover of signaling pathways for pain and neuro-inflammation. The company's lead clinical candidate, SCP-123 (IND Enabling), is efficacious and safe in non-clinical studies, and is one of a series of safer and more potent non-opiod analgesics discovered by the company's founder, Dr. Nicolas Bazan. SCP's focus is translating early-stage compounds into clinical candidates. SCP is currently funded by SBIR grants, and is seeking to raise its first round of venture financing.

N
Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

N
NeuroMolecular Pharmaceuticals

NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.